Skip to main content
. 2020 Oct 21;13(10):324. doi: 10.3390/ph13100324

Figure 2.

Figure 2

Composition of the market for TNFα inhibitors in terms of individual products from 2010 to 2018. The sales volume (DDDs) for infliximab (originator + biosimilars), etanercept (originator + biosimilars), adalimumab (originator + biosimilars), certolizumab pegol and golimumab is expressed as a share of the total volume of TNFα inhibitors.